Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

J Gastrointest Oncol. 2021 Apr;12(2):906-909. doi: 10.21037/jgo-20-230.

Authors

Verena Schlintl¹, Florian Huemer¹, Richard Greil¹, Lukas Weiss¹

Affiliation

¹ Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology, and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, Salzburg, Austria.

No abstract available

Publication types

Comment